Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research note published on Tuesday morning. The firm issued a hold rating on the medical research company’s stock.

Accelerate Diagnostics Stock Down 7.6 %

Accelerate Diagnostics stock opened at $1.57 on Tuesday. The firm’s fifty day moving average price is $1.81 and its two-hundred day moving average price is $1.54. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $5.23.

Insider Transactions at Accelerate Diagnostics

In other news, Director John Patience bought 200,000 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the completion of the acquisition, the director now directly owns 653,224 shares in the company, valued at approximately $1,025,561.68. This trade represents a 44.13 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 43.60% of the company’s stock.

Institutional Investors Weigh In On Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd bought a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics as of its most recent SEC filing. 17.14% of the stock is owned by hedge funds and other institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.